Immutep’s eftilagimod alpha has not so much beaten Keytruda as joined it. An investigator-initiated study has shown that addition of the LAG-3 immunotherapy to the standard-of-care first-line non-small cell lung cancer regimen of Merck & Co’s checkpoint inhibitor plus chemo improved survival by around 10 months.
Key Takeaways
- An open-label academic trial of Immutep’s eftilagimod alpha plus Merck & Co’s Keytruda and chemo in first-line non-small cell lung cancer shows overall survival 10 months longer than in a comparable trial of the latter two.
The data are good in themselves but are also important since they derisk Immutep’s own pivotal TACTI-004 trial, which has...
